Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 330

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study

Open access
Worst, Barbara C., van Tilburg, Cornelis M., Balasubramanian, Gnana Prakash, Fiesel, Petra, Witt, Ruth, Freitag, Angelika, Boudalil, Miream, Previti, Christopher, Wolf, Stephan, Schmidt, Sabine, Chotewutmontri, Sasithorn, Bewerunge-Hudler, Melanie, Schick, Matthias, Schlesner, Matthias, Hutter, Barbara, Taylor, Lenka, Borst, Tobias, Sutter, Christian, Bartram, Claus R., Milde, Till, Pfaff, Elke, Kulozik, Andreas E., von Stackelberg, Arend, Meisel, Roland, Borkhardt, Arndt, Reinhardt, Dirk, Klusmann, Jan-Henning, Fleischhack, Gudrun, Tippelt, Stephan, Dirksen, Uta, Jürgens, Heribert, Kramm, Christof M., von Bueren, Andre O., Westermann, Frank, Fischer, Matthias, Burkhardt, Birgit, Wößmann, Wilhelm, Nathrath, Michaela, Bielack, Stefan S., Frühwald, Michael C., Fulda, Simone, Klingebiel, Thomas, Koscielniak, Ewa, Schwab, Matthias, Tremmel, Roman, Driever, Pablo Hernáiz, Schulte, Johannes H., Brors, Benedikt, von Deimling, Andreas, Lichter, Peter, Eggert, Angelika, Capper, David, Pfister, Stefan M., Jones, David T.W., Witt, Olaf·2016·European Journal of Cancer

Abstract

The 'Individualized Therapy for Relapsed Malignancies in Childhood' (INFORM) precision medicine study is a nationwide German program for children with high-risk relapsed/refractory malignancies, which aims to identify therapeutic targets on an individualised basis. In a pilot phase, reported here, we developed the logistical and analytical pipelines necessary for rapid and comprehensive molecular profiling in a clinical setting. Fifty-seven patients from 20 centers were prospectively recruited. Malignancies investigated included sarcomas (n = 25), brain tumours (n = 23), and others (n = 9). Whole-exome, low-coverage whole-genome, and RNA sequencing were complemented with methylation and expression microarray analyses. Alterations were assessed for potential targetability according to a customised prioritisation algorithm and subsequently discussed in an interdisciplinary molecular tumour board. Next-generation sequencing data were generated for 52 patients, with the full analysis possible in 46 of 52. Turnaround time from sample receipt until first report averaged 28 d. Twenty-six patients (50%) harbored a potentially druggable alteration with a prioritisation score of 'intermediate' or higher (level 4 of 7). Common targets included receptor tyrosine kinases, phosphoinositide 3-kinase-mammalian target of rapamycin pathway, mitogen-activated protein kinase pathway, and cell cycle control. Ten patients received a targeted therapy based on these findings, with responses observed in some previously treatment-refractory tumours. Comparative primary relapse analysis revealed substantial tumour evolution as well as one case of unsuspected secondary malignancy, highlighting the importance of re-biopsy at relapse. This study demonstrates the feasibility of comprehensive, real-time molecular profiling for high-risk paediatric cancer patients. This extended proof-of-concept, with examples of treatment consequences, expands upon previous personalised oncology endeavors, and presents a model with considerable interest and practical relevance in the burgeoning era of personalised medicine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2016.06.009

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 330

Metadata

Authors
Worst, B. C., van Tilburg, C. M., Balasubramanian, G. P., Fiesel, P., Witt, R., Freitag, A., Boudalil, M., Previti, C., Wolf, S., Schmidt, S., Chotewutmontri, S., Bewerunge-Hudler, M., Schick, M., Schlesner, M., Hutter, B., Taylor, L., Borst, T., Sutter, C., Bartram, C. R., Milde, T., Pfaff, E., Kulozik, A. E., von Stackelberg, A., Meisel, R., Borkhardt, A., Reinhardt, D., Klusmann, J.-H., Fleischhack, G., Tippelt, S., Dirksen, U., Jürgens, H., Kramm, C. M., von Bueren, A. O., Westermann, F., Fischer, M., Burkhardt, B., Wößmann, W., Nathrath, M., Bielack, S. S., Frühwald, M. C., Fulda, S., Klingebiel, T., Koscielniak, E., Schwab, M., Tremmel, R., Driever, P. H., Schulte, J. H., Brors, B., von Deimling, A., Lichter, P., Eggert, A., Capper, D., Pfister, S. M., Jones, D. T. W., & Witt, O.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2016-09
Volume
65
Pages
91-101
ISSN
0959-8049 (ISSN-L)
OpenAlex
W2503515884
Cited by
330
References
33
FWCI
12.49
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.